LogoCrystal's Coder Hub

H34.8130

32 min read

👁️ ICD-10 CM H34.8130 — Central Retinal Vein Occlusion, Bilateral, With Macular Edema

Billable Code Confirmed

ICD-10 CM H34.8130 is a fully specified, 7-character ICD-10-CM code valid for all HIPAA-covered transactions from October 1, 2025 through September 30, 2026 under the FY2026 edition. The 7th character “0” (with macular edema) is the clinically decisive axis that distinguishes this code from its bilateral CRVO siblings — H34.8131 (with retinal neovascularization) and H34.8132 (stable) — and must be supported by documented clinical findings such as OCT-confirmed cystoid macular edema or fluorescein angiographic leakage. This code replaces the prior 6-character code H34.813 (Central retinal vein occlusion, bilateral), which was retired when the 7th character clinical status axis was introduced.1,2

Non-Billable Parent Codes

H34 (Retinal vascular occlusions) is the non-billable category header — it encompasses all retinal artery and vein occlusions and cannot be submitted for reimbursement as it lacks the specificity of vessel type, laterality, and clinical status required for valid claim submission. H34.81 (Central retinal vein occlusion) is a non-billable subcategory that identifies the vessel type but is missing both the laterality (character 6) and the clinical status (character 7) axes; no claim should carry H34.81 as a submitted diagnosis. H34.813 (Central retinal vein occlusion, bilateral) is the non-billable 6-character parent of H34.8130 — it specifies bilateral laterality but omits the required 7th character for clinical status (macular edema vs. neovascularization vs. stable); claims submitted with this code will be rejected as non-specific under ICD-10-CM FY2026 rules.1

Clinical Context

The distinction between the three bilateral CRVO clinical status codes is driven entirely by documented findings at the time of the encounter, not by historical diagnosis: H34.8130 requires active macular edema confirmed on OCT or FA; H34.8131 requires documented retinal neovascularization on fundoscopy, FA, or imaging; and H34.8132 applies only when prior CRVO has resolved without active macular edema or neovascularization at the current encounter. The clinical status code should be updated at each encounter to reflect the patient’s current retinal status — a patient previously coded as H34.8130 may appropriately transition to H34.8132 (stable) once treatment achieves macular edema resolution, or may progress to H34.8131 if neovascularization develops. Coders must review the current encounter documentation carefully and not carry forward the prior visit’s 7th character without confirming that the clinical status remains unchanged.2,4

Code Classification

ICD-10 CM H34.8130 is a principal/first-listed diagnosis code representing a definitive retinal vascular disease — it is NOT a manifestation code requiring a “code first” underlying condition, and it is NOT excluded from use as the principal diagnosis for inpatient admission. When bilateral CRVO with macular edema is the condition responsible for inpatient admission, H34.8130 is correctly sequenced as the principal diagnosis; underlying systemic conditions (hypertension, diabetes, thrombophilia) are reported as additional diagnoses per ICD-10-CM Official Guidelines Section II and Section III sequencing rules.2

🔍 Code Description

ICD-10 CM H34.8130 represents bilateral central retinal vein occlusion (CRVO) with active macular edema — the most visually threatening and clinically urgent subtype of bilateral CRVO. Central retinal vein occlusion occurs when the central retinal vein, which drains blood from all four quadrants of the retina, becomes obstructed at or just posterior to the optic nerve head, typically at the lamina cribrosa where the vein is anatomically constrained. The resulting venous stasis triggers a cascade of increased hydrostatic pressure, breakdown of the blood-retinal barrier, vascular leakage, and accumulation of fluid in the macular layers — the condition captured in the “with macular edema” 7th character of this code. The bilateral designation (6th character = 3) reflects simultaneous or sequential involvement of both eyes, a clinical finding that substantially narrows the etiologic differential and urgently raises the probability of a systemic hypercoagulable state, hematologic malignancy, or systemic vasculitis rather than the isolated hypertensive/arteriosclerotic mechanism that drives most unilateral CRVO cases (H34.8110, H34.8120).3,4,5

The “with macular edema” specification in H34.8130 is clinically and codingwise distinct from the neovascularization variant (H34.8131) and the stable variant (H34.8132). Macular edema in CRVO results from accumulation of intraretinal and subretinal fluid in the macula — the area of the retina responsible for central, high-acuity vision — and is the primary driver of the acute visual acuity loss that most patients with CRVO experience. Confirmation of macular edema requires objective documentation: optical coherence tomography (OCT) showing increased central macular thickness, cystoid spaces, or subretinal fluid is the standard of care, or fluorescein angiographic evidence of perifoveal leakage may substitute when OCT is unavailable. Clinically important downstream complications uniquely tied to the macular edema phase include formation of epiretinal membrane, subretinal fibrosis, and photoreceptor atrophy if edema is prolonged or undertreated — complications that may ultimately shift the coding to H34.8132 (stable, residual damage) or require additional diagnosis codes for retinal structural damage if documented separately by the provider.4,5,6

🌳 Code Tree / Hierarchy

H34 Retinal vascular occlusions ❌ Non-billable
│
├── H34.0 Transient retinal artery occlusion ❌ Non-billable
│   ├── H34.01 ...right eye ✅ Billable
│   ├── H34.02 ...left eye ✅ Billable
│   └── H34.03 ...bilateral ✅ Billable
│
├── H34.1 Central retinal artery occlusion ❌ Non-billable
│   ├── H34.11 ...right eye ✅ Billable
│   ├── H34.12 ...left eye ✅ Billable
│   └── H34.13 ...bilateral ✅ Billable
│
└── H34.8 Other retinal vascular occlusions ❌ Non-billable
│
├── H34.81 Central retinal vein occlusion ❌ Non-billable
│   │
│   ├── H34.811 ...right eye ❌ Non-billable
│   │   ├── H34.8110 ...right eye, with macular edema ✅ Billable
│   │   ├── H34.8111 ...right eye, with retinal neovascularization ✅ Billable
│   │   └── H34.8112 ...right eye, stable ✅ Billable
│   │
│   ├── H34.812 ...left eye ❌ Non-billable
│   │   ├── H34.8120 ...left eye, with macular edema ✅ Billable
│   │   ├── H34.8121 ...left eye, with retinal neovascularization ✅ Billable
│   │   └── H34.8122 ...left eye, stable ✅ Billable
│   │
│   ├── H34.813 ...bilateral ❌ Non-billable
│   │   ├── H34.8130 ...bilateral, with macular edema ◀ THIS CODE ✅ Billable
│   │   ├── H34.8131 ...bilateral, with retinal neovascularization ✅ Billable
  │   │   └── H34.8132 ...bilateral, stable ✅ Billable
│   │
│   └── H34.819 ...unspecified eye ❌ Non-billable
│       ├── H34.8190 ...unspecified, with macular edema ✅ Billable
│       ├── H34.8191 ...unspecified, with retinal neovascularization ✅ Billable
│       └── H34.8192 ...unspecified, stable ✅ Billable
│
├── H34.82 Venous engorgement ❌ Non-billable
│   ├── H34.821 ...right eye ✅ Billable
│   ├── H34.822 ...left eye ✅ Billable
│   └── H34.823 ...bilateral ✅ Billable
    │
   └── H34.83 Tributary (branch) retinal vein occlusion ❌ Non-billable
├── H34.831 ...right eye ❌ Non-billable
│   ├── H34.8310 ...right eye, with macular edema ✅ Billable
│   ├── H34.8311 ...right eye, with retinal neovascularization ✅ Billable
│   └── H34.8312 ...right eye, stable ✅ Billable
└── H34.832 ...left eye ❌ Non-billable
├── H34.8320 ...left eye, with macular edema ✅ Billable
├── H34.8321 ...left eye, with retinal neovascularization ✅ Billable
  └── H34.8322 ...left eye, stable ✅ Billable

7th Character Is Not Optional — It Is Required for Billability

The 6-character parent H34.813 (Central retinal vein occlusion, bilateral) was retired and is no longer valid for claim submission in FY2026. The 7th character — 0 (with macular edema), 1 (with retinal neovascularization), or 2 (stable) — is mandatory, and its selection must be directly supported by documentation from the current encounter, not carried forward from a prior visit without clinical re-evaluation. A claim submitted with H34.813 as a 6-character code will be rejected by clearinghouses and CMS processing systems as a non-specific code.1,2

Bilateral vs. Unilateral: Always Default to the More Specific Laterality Code

When both eyes are documented with CRVO, use the bilateral code (H34.8130) rather than two separate unilateral codes (H34.8110 and H34.8120). The ICD-10-CM Official Guidelines instruct coders to use the bilateral code when available; reporting two unilateral codes for a condition with a designated bilateral code constitutes a coding error under FY2026 guidelines. If the two eyes have different clinical statuses (e.g., right eye with macular edema and left eye stable), separate unilateral codes ARE correct — H34.8110 (right) and H34.8122 (left) — because no bilateral code captures mixed clinical statuses.2

✅ Includes

  • Active bilateral CRVO at any stage with OCT-confirmed central macular thickness elevation, cystoid macular edema, or subretinal fluid attributable to bilateral venous outflow obstruction at the central retinal vein; the “with macular edema” designation applies as long as macular edema is documented at the current encounter regardless of prior treatment response or duration of disease.1,2
  • Bilateral ischemic CRVO presenting with extensive capillary nonperfusion AND macular edema where the predominant coding driver at this encounter is the macular edema rather than neovascularization; if neovascularization is also present and separately documented, query the provider about which finding is the primary diagnosis for this encounter before selecting between H34.8130 and H34.8131.2
  • Bilateral non-ischemic (perfused) CRVO with macular edema, as ischemic vs. non-ischemic classification is not captured at the ICD-10-CM code level and does not change the H34.8130 assignment; the distinction is clinically important for treatment but not for code selection.4
  • Bilateral macular retinal edema specifically attributable to bilateral central retinal vein occlusion, confirmed by provider documentation linking the macular edema to the CRVO etiology; if the provider attributes macular edema to diabetic retinopathy rather than CRVO, the appropriate diabetic eye disease code from the E11.3xx series applies instead.2
  • Recurrent bilateral CRVO in a previously treated patient presenting at a follow-up encounter with documented active macular edema on OCT or FA; the 7th character status is determined by the findings at this encounter, not by the historical diagnosis or prior code assignment.2

❌ Excludes

Excludes 1

Type 1 Excludes — Do Not Code Together

The most common Excludes 1 error for H34.8130 is assigning both H34.8130 and a code for amaurosis fugax (G45.3) on the same encounter or inpatient stay. Amaurosis fugax (transient monocular vision loss from a temporary retinal ischemic event) is by definition a transient, reversible event — it is mutually exclusive with the permanent structural occlusion represented by CRVO. If a patient with CRVO history subsequently develops a transient visual episode, the provider must document whether this is a new amaurosis fugax event vs. fluctuation of the existing CRVO before the coder selects a diagnosis; they cannot be coded together under any circumstances.1,2

G45.3 — Amaurosis fugax is placed in a Type 1 Excludes relationship at the H34 category level. Amaurosis fugax describes transient monocular vision loss caused by a temporary retinal arterial occlusion (most commonly embolic) that resolves completely within 24 hours; it is biologically and clinically incompatible with the permanent venous obstruction and structural macular edema captured in H34.8130. This exclusion applies to all codes within the H34 category — coders encountering a patient with a history of both amaurosis fugax and CRVO must sequence only the active, current-encounter condition and not report both codes simultaneously.1,2

Excludes 2

Diabetic macular edema codes (E11.311, E11.3411, etc.) carry a Type 2 Excludes relationship with H34.8130 in the sense that when a patient has both Type 2 diabetes with documented diabetic macular edema AND CRVO with macular edema — two independently documented pathologies — BOTH the appropriate E11.3xx diabetic retinopathy/macular edema code AND H34.8130 should be assigned. The provider must document that both conditions are present and active; the retinal specialist’s note must attribute the macular edema to CRVO (coded as H34.8130) while the diabetologist’s documentation supports the diabetic maculopathy code. Coders should not assume that one etiology excludes the other without explicit provider documentation.2,4

📋 Clinical Overview

Bilateral CRVO Clinical Status — Code Selection by Encounter Findings

The three 7th character variants of bilateral CRVO represent distinct clinical phases in the natural history and treatment response of the disease rather than permanently assigned states. A single patient may legitimately be coded with all three codes across different encounters as their clinical status evolves: initial presentation with H34.8130 (active macular edema), followed by H34.8131 if neovascularization develops despite treatment, and ultimately H34.8132 once both macular edema and neovascularization have resolved under therapy. The table below summarizes the key distinguishing features to support accurate 7th character selection at each encounter.2,4,5

FeatureH34.8130 Bilateral, with Macular EdemaH34.8131 Bilateral, with Retinal NeovascularizationH34.8132 Bilateral, Stable
Defining clinical findingActive intraretinal or subretinal fluid accumulation in the macula confirmed by OCT (central macular thickness > 250 µm or cystoid spaces) or fluorescein angiographic leakage in the perifoveal region; this is typically the presenting finding in acute-to-subacute bilateral CRVONew retinal or iris neovascularization (rubeosis iridis) documented on slit-lamp examination, fundoscopy, wide-field FA, or OCT-angiography; represents progression to the ischemic, proliferative phase of bilateral CRVO and carries substantially higher risk for neovascular glaucoma and vitreous hemorrhageAbsence of active macular edema on current OCT and absence of active neovascularization on current clinical examination; may represent successful treatment response, spontaneous resolution, or burned-out ischemic phase with photoreceptor atrophy — the provider’s note must explicitly support “stable” status
Primary treatment implicationAnti-VEGF intravitreal injections (67028) and/or dexamethasone implant (Ozurdex) as first-line; imaging-guided dosing strategy based on serial OCT; systemic workup for thrombophilia is urgent when bilateral involvement is confirmedPanretinal photocoagulation (PRP) to ablate ischemic retina and reduce VEGF drive; anti-VEGF agents for concurrent macular edema; neovascular glaucoma management if iris neovascularization is present — may trigger 67028 for macular edema AND a laser code for PRPObservation with periodic OCT monitoring; management of systemic risk factors (hypertension I10, hyperlipidemia); no active intravitreal treatment typically required; may still carry low-vision and legal driving restrictions
Sequencing and coding noteFirst-listed or principal diagnosis when bilateral CRVO with macular edema is the reason for the encounter or inpatient admission; always document both OCT findings AND the specific bilateral nature of the CRVO in the encounter note to support this codeDocument neovascularization specifically and separately from macular edema; if both macular edema and neovascularization are present bilaterally, provider must indicate the predominant clinical finding for the encounter — the code captures only one 7th character per bilateral CRVO episodeUse this code only when the provider explicitly documents “stable” or documents resolution of macular edema and neovascularization; do not infer stability from the absence of treatment — provider attestation is required for audit defensibility
Risk for DRG grouping shiftDRG 123 (Neurological Eye Disorders); does not split by CC/MCCDRG 123; same single-tier groupingDRG 123; same grouping regardless of stability

CDI Trigger — Confirm Bilateral Status Before Assigning H34.8130

When the encounter documentation describes “central retinal vein occlusion with macular edema” without explicitly confirming bilateral involvement, a clinical documentation improvement (CDI) query to the provider is indicated before assigning H34.8130. Using a bilateral code when only one eye is documented as affected misrepresents the clinical picture, overstates complexity, and may create inconsistency between the ICD-10-CM code and the CPT modifiers (-E3, -E1, -RT, -LT) used on the associated procedure codes. The provider must explicitly document “bilateral” or specify both right and left eye involvement at the current encounter for H34.8130 to be defensible on audit.2

Manifestations & Symptom Burden

  • Bilateral acute visual acuity loss — typically presents as sudden or subacute painless decrease in central vision in both eyes; severity ranges from mild (count fingers) to profound (light perception only) depending on the degree of macular edema and ischemia; bilateral simultaneous presentation is a rare but serious finding that strongly suggests a systemic etiology requiring urgent workup.3,4
  • Cystoid macular edema (CME) — the defining feature of H34.8130; characterized by fluid-filled cystic spaces within the inner nuclear and outer plexiform layers of the macula, detectable on spectral-domain OCT as loss of the normal foveal contour and elevated central macular thickness; central scotoma and metamorphopsia are the classic visual symptoms.4,5
  • Diffuse retinal hemorrhages — “blood and thunder” fundus with flame-shaped hemorrhages in all four retinal quadrants of both eyes, tortuous and dilated retinal veins, disc edema, and cotton-wool spots visible on fundoscopy; these findings support the diagnosis clinically even before OCT confirmation of macular edema.5
  • Relative afferent pupillary defect (RAPD) — when bilateral CRVO affects both eyes asymmetrically, a RAPD may be detectable on clinical examination; when both eyes are equally affected, RAPD may be absent despite bilateral severe ischemia — this should not dissuade the provider from diagnosing bilateral CRVO when bilateral hemorrhages are visible.5
  • Secondary neovascular complications — if H34.8130 is not adequately treated, bilateral CRVO may progress to H34.8131 (neovascularization) and subsequently to neovascular glaucoma (H40.51xx series), vitreous hemorrhage (H43.1xx series), or tractional retinal detachment — each of which requires additional diagnosis codes and may alter the treatment pathway and associated CPT procedure codes.4,5

OCT Documentation Drives the 7th Character — Without It, Query the Provider

The 7th character “0” (with macular edema) in H34.8130 requires specific documentation of active macular edema at the current encounter. Best practice is for the provider note to state “OCT demonstrates bilateral cystoid macular edema with central macular thickness of X µm OD and Y µm OS consistent with bilateral CRVO” or equivalent language. In the absence of explicit macular edema documentation, coders cannot assign the “0” 7th character based on clinical inference alone; the appropriate action is a CDI query rather than defaulting to H34.8132 (stable) or a less-specific code. Fluorescein angiography documenting perifoveal leakage is an acceptable alternative when OCT is not available.2,4

💰 HCC Risk Adjustment

ComponentDetail
HCC Category (CMS-HCC V28)N/A — Not mapped; verify against current model year
RAF Weight0.000 — No risk adjustment contribution from H34.8130 itself
Chronic Condition Indicator❌ Not classified as an HCC-eligible chronic condition in V28
CMS-HCC V28 ChapterNot included
RADV Audit RelevanceNot applicable — not an HCC code
Commercial Risk ModelVerify against plan-specific HCC model (HHS-HCC for marketplace)

ICD-10 CM H34.8130 does not contribute to CMS-HCC V28 risk scores or RAF calculations for Medicare Advantage plans. Coders should note that the systemic comorbidities most commonly documented alongside bilateral CRVO DO carry HCC relevance and must be coded to full specificity as additional diagnoses: Type 2 diabetes mellitus with specified complications (HCC 19 and related categories in V28), hypertensive heart and chronic kidney disease combinations, and certain hypercoagulable states may all be HCC-relevant depending on the specific code selected. Documentation completeness for these underlying conditions is therefore critical even though H34.8130 itself does not add RAF weight — undercoding comorbidities in a patient with bilateral CRVO represents a risk adjustment capture gap that CDI should address proactively. Verify all HCC assignments against the current year’s CMS-HCC V28 model output files before finalizing risk adjustment submissions.6,7

🏥 MS-DRG Assignment

ComponentValue
MDC02 — Diseases and Disorders of the Eye
Principal DRGDRG 123 — Neurological Eye Disorders (MS-DRG v43.0)
DRG with MCCN/A — DRG 123 is single-tier; no MCC variant
DRG with CCN/A — DRG 123 is single-tier; no CC variant
DRG without CC/MCCDRG 123 — Neurological Eye Disorders
GMLOS(Verify against CMS FY2026 IPPS Final Rule, CMS-1839-F, Table 5)
DRG Weight(Verify against CMS FY2026 IPPS relative weight tables)
POA IndicatorRequired for inpatient claims; Y = present on admission

ICD-10 CM H34.8130 groups to DRG 123 (Neurological Eye Disorders) under MDC 02 — a single-tier DRG that does not subdivide based on the presence or absence of CCs or MCCs, which is a significant distinction from most MDC 02 DRGs such as the DRG 124/125/126 family used for other ophthalmic disorders. Because DRG 123 does not split, the documentation of comorbidities does not shift the DRG assignment for this code; however, complete comorbidity coding remains essential for accurate GMLOS benchmarking, case mix index reporting, CDI performance metrics, and accurate present-on-admission (POA) indicator assignment. Inpatient admission for bilateral CRVO with macular edema should be supported by documentation of clinical severity (bilateral acute vision loss, inability to safely function at home, need for urgent systemic workup), as CRVO is primarily an outpatient-managed condition and inpatient utilization review will scrutinize the medical necessity basis for admission. The principal diagnosis should be sequenced as H34.8130 when bilateral CRVO with macular edema is the condition established after study to be primarily responsible for the inpatient admission; if the patient was admitted for a systemic condition (e.g., newly diagnosed antiphospholipid syndrome discovered during the workup) that drove the hospitalization, that systemic code would sequence as principal instead.2,7

🔗 Related ICD-10-CM Codes

Central Retinal Vein Occlusion — Full Status/Laterality Family

CodeDescriptionRelationship to H34.8130
H34.8110Central retinal vein occlusion, right eye, with macular edemaUnilateral right-eye equivalent; use when CRVO with macular edema is confirmed in the right eye only; do not report with H34.8130 (bilateral code captures both eyes)
H34.8120Central retinal vein occlusion, left eye, with macular edemaUnilateral left-eye equivalent; same logic as H34.8110
H34.8131Central retinal vein occlusion, bilateral, with retinal neovascularizationBilateral CRVO sibling — proliferative/ischemic phase; select over H34.8130 when neovascularization is the predominant documented finding at this encounter
H34.8132Central retinal vein occlusion, bilateral, stableBilateral CRVO sibling — resolved/stable phase; select when provider documents resolution of macular edema and absence of active neovascularization at the current encounter
H34.8190Central retinal vein occlusion, unspecified eye, with macular edemaLeast-specific CRVO code with macular edema; appropriate only when laterality is genuinely undetermined after provider query — not a substitute for H34.8130 when bilateral status is documented

Frequently Associated Comorbidities and Complications

CodeDescriptionRelationship to H34.8130
I10Essential (primary) hypertensionMost common systemic risk factor for CRVO; code as additional diagnosis when documented; not an Excludes relationship — code both
H34.8310Tributary (branch) retinal vein occlusion, right eye, with macular edemaDifferent vessel — branch vs. central; not reportable together with H34.8130 for the same eye
H34.8320Tributary (branch) retinal vein occlusion, left eye, with macular edemaBranch RVO, left eye — reportable separately from H34.8130 only if bilateral CRVO AND unilateral branch RVO of a different vessel are independently documented
H34.821Venous engorgement, right eyeDistinct entity from CRVO; venous engorgement without frank occlusion — document the provider’s specific diagnosis before selecting between H34.821x and H34.8110
G45.3Amaurosis fugaxExcludes 1 at H34 level — NEVER code together with H34.8130

🛠️ Commonly Associated CPT Codes

67028 — Intravitreal injection of pharmacologic agent (specify) This is the primary therapeutic procedure for CRVO-associated macular edema; anti-VEGF agents (bevacizumab, ranibizumab, aflibercept, faricimab) and corticosteroid implants (dexamethasone [Ozurdex], fluocinolone acetonide) are the most common injectates. When bilateral intravitreal injections are performed in the same session, report 67028 twice using eye-specific modifiers (-E3 for right, -E1 for left, or -RT and -LT); the MUE for 67028 is 1(3) per eye per date of service, and documentation must support each injection as a separately necessary intervention for the independently affected eye.2,3

92134 — Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report OCT of the posterior segment is the standard of care for monitoring macular edema in CRVO and directly drives the 7th character selection for H34.8130; the OCT report must document findings bilaterally when H34.8130 is the assigned code. When performed bilaterally on the same date as an intravitreal injection, 92134 is separately reportable with 67028 per CPT coding guidelines; append RT and LT or E-modifiers to specify the eye(s) imaged.3

92235 — Fluorescein angiography with interpretation and report, unilateral or bilateral FA is used for diagnosis, staging of ischemic vs. non-ischemic CRVO, detection of retinal neovascularization, and documentation of macular edema extent; a single billing unit covers bilateral FA performed in the same session. FA findings supporting bilateral leakage and/or capillary nonperfusion in the context of H34.8130 are strong medical necessity documentation for anti-VEGF treatment and should be reflected in the procedure note and coding.3

92250 — Fundus photography with interpretation and report Fundus photographs documenting bilateral “blood and thunder” hemorrhages, dilated tortuous veins, disc edema, and cotton-wool spots provide visual medical necessity evidence for CRVO management and are separately reportable on the same date as diagnostic interpretation services; used for baseline and longitudinal documentation of hemorrhage resolution and disk changes.3

92004 — Ophthalmologic examination and evaluation, new patient, comprehensive 92014 — Ophthalmologic examination and evaluation, established patient, comprehensive Used for the evaluation and management component of a CRVO encounter when a comprehensive ophthalmologic examination is performed; when 92014 is billed on the same date as a procedure like 67028, documentation must support a significant, separately identifiable examination beyond the pre-injection assessment, and modifier -25 must be appended to the E/M code. For established patients on ongoing anti-VEGF therapy for H34.8130, the clinical examination documents treatment response and guides the injection decision.2,3

67221 — Destruction of localized lesion of choroid (including retinal photocoagulation), unilateral or bilateral; photocoagulation Panretinal photocoagulation (PRP) is indicated when bilateral CRVO progresses to H34.8131 (retinal neovascularization); when documented neovascularization is present at the same encounter alongside macular edema, the provider must specify the primary diagnosis for coding purposes before the 7th character is selected. 67221 may be reported bilaterally with appropriate eye-specific modifiers when PRP is performed on both eyes; NCCI edits should be reviewed when billing 67028 and 67221 on the same date of service for the same eye.3

NCCI Bundling Considerations

CPT 67028 (intravitreal injection) and 92134 (OCT posterior segment) are generally separately reportable on the same date of service because the OCT provides independent diagnostic information that drives treatment decisions and is not considered bundled into the injection procedure payment. However, some payers apply MPPR (Multiple Procedure Payment Reduction) to multiple imaging services performed on the same date; the second and subsequent diagnostic imaging services may be reimbursed at 50–80% of the single-service fee schedule rate depending on payer contract terms. When 67028 and 67221 (laser photocoagulation) are performed for the same eye on the same date, the NCCI edit status must be verified — these two procedures may be bundled when performed for the same clinical indication (both targeting neovascularization), but may be separately reportable when performed for distinct indications (injection for macular edema, laser for neovascularization) with appropriate modifier -59 documentation of the distinct indication and anatomic site.2,3

🔬 ICD-10-PCS Crosswalk

For inpatient facility coding, the ICD-10-PCS codes for procedures performed in the management of H34.8130 depend on the specific intervention. Anti-VEGF intravitreal injection is the most common procedure; inpatient admission specifically for CRVO management is uncommon but may occur for severe bilateral disease, systemic workup for hypercoagulable state, or when a patient cannot be managed safely outpatient. The PCS codes below address the two most clinically relevant inpatient intervention types for bilateral CRVO with macular edema.2,5

PCS CodeFull DescriptionProcedure Type
3E0C3MZIntroduction, Eye, Right, Percutaneous Approach, Monoclonal AntibodyIntravitreal anti-VEGF injection, right eye — for bevacizumab, ranibizumab, aflibercept, faricimab administered by intravitreal route; Character 6 M = Monoclonal Antibody captures the anti-VEGF drug class. Assign separately from the left-eye code when bilateral injections are performed at the same inpatient session.
3E0D3MZIntroduction, Eye, Left, Percutaneous Approach, Monoclonal AntibodyIntravitreal anti-VEGF injection, left eye — same root operation and substance as 3E0C3MZ; required as a separate code line when both eyes receive anti-VEGF injection during the inpatient stay; ICD-10-PCS has no bilateral procedure modifier equivalent.
3E0C33ZIntroduction, Eye, Right, Percutaneous Approach, Anti-inflammatoryIntravitreal corticosteroid injection or implant, right eye — applies to dexamethasone implant (Ozurdex) or triamcinolone acetonide administered by intravitreal route; Character 6 = 3 (Anti-inflammatory) differentiates steroid injections from anti-VEGF agents.
3E0D33ZIntroduction, Eye, Left, Percutaneous Approach, Anti-inflammatoryIntravitreal corticosteroid injection or implant, left eye — use when the left eye receives steroid treatment; assign as a separate code line from 3E0C33Z if both eyes are treated with steroids during the same inpatient encounter.

💊 Coding Scenarios and Examples

Scenario 1 — Outpatient: Bilateral Anti-VEGF Injections for Active Macular Edema

Clinical Scenario: A 58-year-old male with a known 3-month history of bilateral central retinal vein occlusion presents for a scheduled anti-VEGF injection visit. Today’s OCT report states: “OS: central macular thickness 498 µm, intraretinal cystoid spaces present. OD: central macular thickness 462 µm, subretinal fluid present. Consistent with bilateral CRVO with active macular edema bilaterally.” The physician performs bilateral intravitreal injections of aflibercept (Eylea) 2.0 mg in both eyes under sterile technique. The injection note documents each eye’s preparation, anesthetic, and injection separately. A brief pre-injection examination is performed but does not constitute a separately identifiable, significant E/M service.

Correct Coding:

  • 67028-E3 — Intravitreal injection, right upper — actually for intravitreal injections, use RT/LT or E-modifiers for laterality; E3 = right upper eye; however, for intravitreal injections, standard practice is RT/LT (not E-modifiers which are for eyelid procedures); use 67028-RT for right eye intravitreal injection
  • 67028-LT--51 — Intravitreal injection, left eye; modifier -51 applies to the second injection as a multiple procedure
  • H34.8130 — Principal/first-listed diagnosis: bilateral CRVO with macular edema, documented bilaterally on OCT at this encounter
  • I10 — Additional diagnosis: essential hypertension documented in the chart as a relevant comorbidity

Sequencing Explanation: H34.8130 is the first-listed diagnosis because it is the reason for the encounter. The systemic comorbidities (I10) are coded as additional diagnoses. Two separate lines for 67028 with RT/LT modifiers are required because two distinct injections were performed on two separate eyes with separate documentation, separate anesthetic, and separate injection procedures — this is not a single bilateral service under a -50 modifier for intravitreal injections.1,2,3

CDI Note: The OCT report must specifically document bilateral macular edema with central macular thickness values or cystoid space descriptions for each eye to support H34.8130. If the OCT documents one eye as stable and one as active, H34.8130 would not apply — separate unilateral codes (H34.8110 and H34.8122) would be required, and a CDI query to the provider would be appropriate to clarify the bilateral vs. unilateral status.

Scenario 2 — Inpatient Admission: New Bilateral CRVO, Systemic Workup for Hypercoagulable State

Clinical Scenario: A previously healthy 42-year-old woman presents to the emergency department with sudden bilateral painless vision loss of 24 hours duration. Fundoscopic examination reveals classic bilateral “blood and thunder” fundus with diffuse retinal hemorrhages, dilated tortuous veins, and disc edema in both eyes. OCT confirms bilateral cystoid macular edema. The ophthalmologist diagnoses bilateral CRVO with macular edema. Given the unusually young age and bilateral simultaneous presentation — atypical for isolated hypertensive CRVO — the patient is admitted for urgent inpatient hematologic workup. Hypercoagulable panel, lupus anticoagulant, antiphospholipid antibodies, factor V Leiden, and prothrombin gene mutation testing are ordered. The admission workup identifies antiphospholipid antibody syndrome (APS). Bilateral intravitreal anti-VEGF injections are administered during the admission.

Correct Coding:

  • PDx: H34.8130 — Principal diagnosis: bilateral CRVO with macular edema is the reason the patient was admitted (established after study); the APS is a new discovery that explains the bilateral CRVO but H34.8130 remains principal because it drove the admission decision
  • SDx: D68.61 — Antiphospholipid syndrome — additional diagnosis; the hematologic workup finding that explains bilateral CRVO in a young patient; code to full specificity
  • SDx: I10 — Essential hypertension if documented (though less prominent here given young age)
  • PCS: 3E0C3MZ — Introduction, Eye Right, Percutaneous, Monoclonal Antibody (right eye anti-VEGF)
  • PCS: 3E0D3MZ — Introduction, Eye Left, Percutaneous, Monoclonal Antibody (left eye anti-VEGF)

Sequencing Explanation: H34.8130 is sequenced as principal because it is the condition established after study to be primarily responsible for the inpatient admission per ICD-10-CM Official Guidelines Section II. The antiphospholipid syndrome (D68.61) is coded as an additional diagnosis because it was identified during the workup and represents a clinically significant finding that affects ongoing treatment — but it was not the stated reason for admission. Both PCS codes are required on separate lines because ICD-10-PCS assigns a separate procedure code for each body part treated.2,5

CDI Note: The provider must explicitly document the causal relationship between the antiphospholipid syndrome and the bilateral CRVO for the D68.61 code to be reportable as a clinically significant additional diagnosis; “bilateral CRVO in a young patient workup revealed APS” is an acceptable notation. Query the provider if documentation is ambiguous about whether APS is confirmed or still suspected at discharge.

Scenario 3 — Outpatient: Status Change from Macular Edema to Stable — Code Must Change

Clinical Scenario: A 65-year-old woman with previously documented bilateral CRVO with macular edema (H34.8130, coded at her last two visits) returns for a 6-week follow-up after her third bilateral anti-VEGF injection. Today’s OCT report states: “OD: central macular thickness 215 µm, no intraretinal fluid, no subretinal fluid. OS: central macular thickness 228 µm, no cystoid spaces. Bilateral macular edema has resolved. CRVO stable bilaterally.” The physician documents “bilateral CRVO, stable, no active macular edema today” in the assessment. She schedules the patient for a follow-up in 8 weeks with optional re-injection if macular edema recurs.

Correct Coding:

  • H34.8132 — First-listed diagnosis: bilateral CRVO, stable — this visit’s code must reflect the current encounter findings, NOT the prior visit’s H34.8130 code; the OCT objectively documents bilateral resolution of macular edema and provider documentation confirms “stable” status
  • I10 — Additional diagnosis: hypertension (ongoing)
  • No 67028 at this encounter — no injection was performed

Sequencing Explanation: The most critical coding principle illustrated here is that the 7th character must reflect the clinical status at the current encounter — not historical status. H34.8130 was correct at prior visits but is NOT correct today because macular edema has resolved. Using H34.8130 at this encounter when OCT confirms bilateral macular resolution would be a coding error that overstates clinical acuity and could trigger a medical necessity audit for treatments not provided. The transition from H34.8130 to H34.8132 across encounters is expected and appropriate when treatment is working.2,4

CDI Note: The provider’s assessment must include explicit language supporting the “stable” status — “no macular edema on OCT” or “bilateral CRVO stable” are both acceptable. If the provider’s note is ambiguous (e.g., “continuing to monitor”) without stating whether macular edema is present or absent, a CDI query is appropriate before the coder selects between H34.8130 and H34.8132 — the OCT report alone does not substitute for provider documentation of clinical status.

⚠️ Coding Pitfalls and Tips

  • Assigning H34.8130 at every encounter regardless of current clinical findings: The single most common error for CRVO codes is carrying forward the initial code without reviewing the current encounter’s OCT and provider assessment. H34.8130 is appropriate only when active macular edema is documented at the current encounter. Once macular edema resolves, the correct code becomes H34.8132 (stable); if neovascularization appears, H34.8131 applies. Failure to update the 7th character across encounters overstates clinical acuity, creates inconsistency between the diagnosis code and the associated procedure codes, and is a common finding in ophthalmology coding audits.2,4

  • Using two unilateral codes instead of the bilateral code when both eyes are equally affected: When both eyes have the same type of CRVO with the same 7th character status, the bilateral code (H34.8130) must be used rather than H34.8110 + H34.8120. Per ICD-10-CM Official Guidelines, the bilateral code is required when available and the condition is bilateral; reporting two unilateral codes is a coding error. The exception applies only when the two eyes have different 7th character statuses (e.g., right eye with macular edema, left eye stable) — in that case, separate laterality-specific codes are correct because no bilateral code captures mixed clinical statuses.2

  • Submitting the non-billable parent code H34.813 instead of H34.8130: The 6-character code H34.813 (Central retinal vein occlusion, bilateral) was retired with the expansion to 7-character specificity and is no longer a valid FY2026 code. Claims submitted with H34.813 will be rejected as non-specific by Medicare and most commercial payers. Clearing house validation should catch this error, but legacy billing templates or outdated charge description masters (CDMs) that have not been updated to the 7-character codes are a known source of this error in high-volume retina practices — audit the CDM annually for retired codes in the H34.81x family.1,7

  • Failing to code the systemic etiology when bilateral CRVO is caused by a documented underlying systemic condition: Bilateral CRVO in a patient under 50, or bilateral CRVO in any patient with documented hypercoagulable state, hematologic malignancy, autoimmune disease, or vasculitis, requires coding the systemic condition as an additional diagnosis alongside H34.8130. Omitting the systemic etiology understates the clinical complexity of the admission or encounter, creates a CDI gap, and may result in incomplete risk adjustment capture for plans that reward documentation of these underlying conditions. Always review the admission workup and system review documentation for systemic diagnoses that explain the unusual bilateral presentation.2,4

  • Reporting H34.8130 and a diabetic macular edema code simultaneously without provider documentation that both are independently present: When a diabetic patient has CRVO with macular edema, the coder must not assume the macular edema is solely attributable to CRVO without provider documentation specifically distinguishing CRVO-related macular edema from diabetic macular edema. If the provider documents both conditions as independently contributing to the patient’s macular edema, both H34.8130 and the appropriate E11.3xx diabetic retinopathy code may be assigned. If the provider attributes the macular edema to CRVO only, use H34.8130 and an appropriate diabetes code without macular edema specificity. A CDI query is appropriate when the documentation is ambiguous about which disease is driving the macular edema at the current encounter.2,4

  • Omitting the POA (Present on Admission) indicator for inpatient claims: H34.8130 assigned as the principal or secondary diagnosis on an inpatient claim requires a valid POA indicator. For bilateral CRVO presenting as the reason for inpatient admission, the POA indicator should be Y (condition was present at time of inpatient admission) if the CRVO with macular edema was documented on admission. Omitting or incorrectly assigning the POA indicator for H34.8130 can trigger claim edits, affect HAC (hospital-acquired condition) screening, and result in remittance adjustments for inpatient claims where the POA = N would suggest a hospital-acquired ocular vascular event — an extremely implausible clinical scenario that would trigger audit scrutiny.2,7

📚 Sources

¹ Centers for Medicare & Medicaid Services; National Center for Health Statistics. *ICD-10-CM Tabular List of Diseases and Injuries, FY2026 Edition*. Effective October 1, 2025. H34.8130 code entry, code family H34.81xx, and 7th character clinical status axis. Available at: cms.gov/medicare/coding-billing/icd-10-codes. ² Centers for Medicare & Medicaid Services; National Center for Health Statistics. *ICD-10-CM Official Guidelines for Coding and Reporting, FY2026*. Section I.C.7 (Eye and Adnexa), Section II (Selection of Principal Diagnosis), Section III (Reporting Additional Diagnoses). Effective October 1, 2025. Available at: cms.gov. ³ American Medical Association. *CPT 2026 Professional Edition*. Chicago, IL: AMA Press; 2025. CPT codes 67028, 92134, 92235, 92250, 92004, 92014, 67221 — ophthalmology and retinal procedure descriptors. ⁴ American Academy of Ophthalmology Retina/Vitreous Panel. *Preferred Practice Pattern: Retinal Vein Occlusions*. San Francisco, CA: AAO; 2022. Clinical staging, macular edema documentation standards, and ischemic vs. non-ischemic CRVO classification guidance. ⁵ Hayreh SS, Zimmerman MB. *Central Retinal Vein Occlusion: Natural History of Visual Outcome*. JAMA Ophthalmology. 2012;130(5):550-560. Pathophysiology of CRVO, bilateral presentation epidemiology, systemic risk factors. ⁶ Centers for Medicare & Medicaid Services. *CMS-HCC V28 Model — Risk Adjustment Model Documentation and Software*. Released January 2024. HCC mapping tables for FY2024 and FY2025 applicable to H34.8130 (not mapped). Available at: cms.gov/medicare/health-plans/medicareadvtgspecratestats. ⁷ Centers for Medicare & Medicaid Services. *FY2026 IPPS Final Rule (CMS-1839-F) — MS-DRG v43.0 Grouper Documentation and Tables*, including DRG 123 (Neurological Eye Disorders) assignment for H34.8130. Published October 2025. Available at: cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps.

Graph View

Recent Notes